Tuberculosis, Meningeal
A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9)
Drugs by status
Approved for this indication (3)
Phase 3 trials (8)
Phase 2 trials (6)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (13)
- Radboud University
- University of Bordeaux
- All India Institute of Medical Sciences
- University of Indonesia
- Pham Ngoc Thach University of Medicine
- Padjadjaran University
- University of Oxford
- Tropical Diseases Hospital, Ho Chi Minh City
- United States Agency for International Development
- European Union
- Eijkman Institute for Molecular Biology, Jakarta, Indonesia
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Government of France
Organization Involved with Phase 2 Indications (9)
- Global Alliance for TB Drug Development
- University of London
- Johns Hopkins University
- University of California, San Francisco
- University of Cape Town
- University of North Carolina at Chapel Hill
- Medical Research Council-UVRI Uganda Research Unit on AIDS
- B. J. Medical College and Hospital
- National Institute for Research in Tuberculosis, Chennai, India
Organization Involved with Other Experimental Indications (2)